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SUMMARY
forty two to 57% of patients with metastatic renal cell carcinoma (mrCC) receive the second-line therapy according to 
available data. in our analysis we wanted to determine the percentage of patients within intermediate/poor prognostic 
group mRCC who continued the treatment with the second line following progression on the first line and the percentage 
of patients who were not able to receive the second line treatment. Patients received sunitinib (first started on 12 August 
2018) or pazopanib (first started on May 2014) at University Hospital Center Zagreb. The latest treatment started in Decem-
ber 2018. our results show that 39.4% of patients who received sunitinib and 37.9% of patients who received pazopanib, did 
not receive the second line treatment, which is consistent with available data. The question arises whether we could have 
helped those patients if we had access to newer therapeutic options.
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ANALIZA BOLESNIKA S METASTATSKIM RAKOM BUBREGA  
SREDNJE I LOŠE PROGNOSTIČKE SKUPINE  
LIJEČNIH U KLINIČKOM BOLNIČKOM CENTRU ZAGREB
SAŽETAK
prema literaturnim podacima oko 42% do 57% bolesnika s metastatskim karcinomom bubrega primi drugu liniju lije-
čenja. Retrospektivnom analizom naših podataka htjeli smo prikazati postotak bolesnika s metastatskim karcinomom bu-
brega koji pripadaju srednjoj/lošoj prognostičkoj skupini a koji su nastavili liječenje drugom linijom nakon progresije na 
prvolinijsko liječenje. Također smo htjeli prikazati postotak bolesnika koji nisu bili u mogućnosti nastaviti drugolinijsko 
 liječenje. Bolesnici su primali sunitinib (prvi bolesnik je započeo liječenje u svibnju 2014.) i pazopanib (prvi bolesnik je zapo-
čeo liječenje 12. kolovoza 2018) u Kliničkom bolničkom centru Zagreb. Uključeni su bili bolesnici koji su liječenje započeli do 
kraja prosinca 2018. godine. 39.4% bolesnika koji su primali sunitinib i 37.9% bolesnika koji su primali pazopanib, nije pri-
milo drugu liniju liječenja, što se podudara s literaturnim podacima. Nameće se pitanje, jesmo li navedenim bolesnicima 
mogli pomoći da smo imali dostupne novije terapijske opcije.




improved understanding of von Hippel–lin-
dau gene mutations lead to the induction of angio-
genic protein and development of vascular endo-
thelial growth factor (VeGf)-targeted therapies 
with tyrosine kinase inhibitors (TKIs). TKIs suni-
tinib and pazopanib represent a standard first-line 
treatment for patients with clear cell metastatic 
kidney cancer. since 2009, when pazopanib was 
approved by the United states food and Drug ad-
ministration (fDa), no other agent has been ap-
proved for the first-line therapy setting (1).
novel targeted therapies, immune check-
point inhibitors, and immune-modulating drugs 
with promising results in phase iii clinical trials 
are changing the first-line setting, and they are re-
placing sunitinib, pazopanib, as preferred first-
line agents.
in our analysis, we wanted to determine the 
proportion of patients with intermediate/poor 
prognostic group mrCC who continued the treat-
ment with the second line following progression 
on the first line and the proportion of patients who 
were not able to receive the second-line treatment. 
MATERIAL AND METHODS
We analyzed patients who received sunitinib 
or pazopanib at the University Hospital Center 
Zagreb as the first-line treatment for mRCC. First-
line therapy was defined as the first administered 
TKI within the treatment history for mRCC. Sec-
ond-line therapy was any other systemic therapy 
after the first-line TKI treatment. Discontinuation 
of the first-line treatment was due to progressive 
disease, therapy-limiting toxicity, or the patient´s 
request. Patients were treated with the second-line 
therapy when eligible according to applicable 
treatment guidelines and local standards (includ-
ing ECOG status, and laboratory findings). Pro-
gression was defined by radiological evidence of 
the disease progression according to the response 
evaluation criteria in solid tumors (RECIST) crite-
ria, clinical signs of the progression, or death from 
the disease. Treatment and therapeutic monitor-
ing, based on computed tomographic scans every 
three months, were applied according to guide-
lines and local standards. Clinical data were ex-
tracted from medical charts and collected in a da-
tabase. physicians assessed data in an anonymized 
manner following recommendations of the local 
ethics committee and the Helsinki declaration in 
its latest revised version.
all patients were divided into subgroups for 
comparison according to gender, age, eCoG sta-
tus, nephrectomy or kidney biopsy before intro-
duction of first-line therapy, pathohistological 
finding of sarcomatoid component, number (less 
than three or more) and distribution of metastases 
before the onset of systemic therapy, MsKCC 
prognostic group (favorable, intermediate/poor), 
and second-line treatment.
RESULTS
patients started to receive sunitinib on 12 au-
gust 2008 and pazopanib on 16 May 2014. The lat-
est treatment started in December 2018. out of 295 
patients, 181 received sunitinib, and 114 received 
pazopanib. one hundred nine patients (60%) who 
received sunitinib and 66 patients who received 
pazopanib were, according to MsKCC prognostic 
groups, in the intermediate/poor prognostic group. 
Twenty-one patients (19.3%) are still receiving 
sunitinib as the first-line therapy, and 16 patients 
(24.2%) are still receiving pazopanib in the first 
line. a total of 43 patients (39.4%) who received 
sunitinib did not receive the second-line treat-
ment, whereas 45 (41.3%) patients received the 
second-line treatment as follows: 20 (44.4%) nivo-
lumab, 10% axitinib (22.2%), everolimus 11 
(24.4%), other therapies 4 (9%). Twenty-five pa-
tients (37.9%) who received pazopanib did not re-
ceive the second-line treatment, whereas 25 
(37.9%) patients received the second-line treat-
ment as follows: 12 (48%) nivolumab, axitinib 6 
(24%), everolimus 6 (24%) other therapies 1 (4%).
DISCUSSION
Currently, only 42%–57% of patients with 
mrCC receive second-line therapy according to 
previously published data (2,3). our results are 
very similar. The reasons for the high dropout rate 
before patients enter the second-line therapy are 
largely unknown (4). Death related to rapid tumor 
progression during first-line therapy does not ex-
plain this phenomenon sufficiently (5).
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The question arises whether we could have 
helped other patients if we had access to other 
(novel) therapeutic options. it is well known that 
the combination of TKIs and immunotherapy 
yields a better response to therapy, and treatment 
with multiple lines of therapy results in more pro-
longed overall survival. optimizing the treatment 
of mrCC using the combination of immunothera-
py and targeted agents, as well as the possible fa-
vorable sequence of treatments between these two 
classes of drugs, remains an open question at this 
moment.
Another critical question that arises from bet-
ter results from each clinical trial is: Can we afford 
it? rising expenses of such therapies can act as a 
barrier for many patients. The cost of immuno-
therapy for mrCC is following the same trend of 
most new drugs and biologics. The economic bur-
den of mrCC treatment is growing with the in-
creasing use of targeted therapies, and we urgent-
ly need reliable biomarkers of tumor response. 
The results obtained in recent years have raised 
enormous enthusiasm in cancer researchers, 
aimed at identifying, isolating, and validating bio-
markers associated with the dynamics of the tu-
mor environment and the therapeutic response. 
However, we are still waiting for the implementa-
tion of these results into everyday clinical practice.
CONCLUSION
The proportion of patients who were not able 
to receive the second-line treatment in our study is 
in accordance with the previously published data. 
A combination of TKIs and immunotherapy 
showed better response to therapy, and the treat-
ment with multiple lines of therapy results in 
more prolonged overall survival. although still 
unavailable because of the high economic burden 
and lack of predictive biomarkers, we hope that 
mrCC patients will soon have an opportunity for 
more effective novel treatments in the Republic of 
Croatia.
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